Cargando…

Polyautoimmunity in patients with cutaneous lupus erythematosus: A nationwide sex- and age-matched cohort study from Denmark

BACKGROUND: Polyautoimmunity is defined as having 2 or more autoimmune diseases. Little is known about polyautoimmunity in patients with cutaneous lupus erythematosus (CLE). OBJECTIVES: To estimate prevalence and 5-year incidence of non–lupus erythematosus (LE) autoimmune diseases in patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Graven-Nielsen, Christoffer S., Vittrup, Ida.V., Kragh, Anna J., Lund, Fredrik, Bliddal, Sofie, Kofoed, Kristian, Kristensen, Salome, Stensballe, Allan, Nielsen, Claus H., Feldt-Rasmussen, Ulla, Cordtz, René, Dreyer, Lene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550802/
https://www.ncbi.nlm.nih.gov/pubmed/37808964
http://dx.doi.org/10.1016/j.jdin.2023.07.018
Descripción
Sumario:BACKGROUND: Polyautoimmunity is defined as having 2 or more autoimmune diseases. Little is known about polyautoimmunity in patients with cutaneous lupus erythematosus (CLE). OBJECTIVES: To estimate prevalence and 5-year incidence of non–lupus erythematosus (LE) autoimmune diseases in patients with CLE. METHODS: Patients with CLE were identified In the Danish National Patient Registry and each patient was age- and sex-matched with 10 general population controls. Outcome information on non-LE autoimmune diseases was obtained by register-linkage between Danish National Patient Registry and the National Prescription Register. The risk ratio (RR) for prevalent non-LE autoimmune disease at time of CLE diagnosis was calculated in modified Poisson regression; and hazard ratios (HRs) for incident non-LE autoimmune disease were estimated in Cox regression analyses. RESULTS: Overall, 1674 patients with CLE had a higher prevalence of a non-LE autoimmune disease than the comparators (18.5 vs 7.9%; RR 2.4; 95% CI, 2.1 to 2.6). Correspondingly, the cumulative incidence of a non-LE autoimmune disease during 5 years of follow-up was increased for the patients with CLE: HR 3.5 (95% CI, 3.0 to 4.0). LIMITATIONS: Risk of detection and misclassification bias, mainly pertaining to the CLE group. CONCLUSION: Patients with CLE had higher prevalence and 5-year cumulative incidence of a non-LE autoimmune disease than the general population.